MetabolicHuman RCT
Cagrilintide and CagriSema: what the amylin trials found
Alone, cagrilintide cut weight by about 11% in 26 weeks; paired with semaglutide it reached 20% at 68 weeks, but lost a head-to-head against tirzepatide.
Cagrilintide
A long-acting amylin analogue tested alone in phase 2 and with semaglutide (CagriSema) in phase 3 trials; investigational, not yet approved.
- Also known as
- AM833, NN9838, CagriSema (with semaglutide)
- Area
- Metabolic
- Status
- Investigational; CagriSema filed with the FDA in Dec 2025; not approved in the UK or US